Articles
News, editorials, patient stories, and more.
This content is for informational purposes only and does not constitute medical advice. Always consult your doctor or a qualified healthcare provider before making any health decisions. Full Disclaimer
It Runs in the Family: New Data on Hashimoto's Genetic Risk
The largest familial risk study of Hashimoto's ever conducted has quantified just how much your relatives share your risk. First-degree rela...
Read More — It Runs in the Family: New Data on Hashimoto's Genetic Risk »Novartis Ianalumab First Drug to Reduce Disease Activity and Patient Burden in Sjögren's Disease Phase III Trials
Novartis announces that ianalumab, a dual-mechanism B-cell depleting antibody, achieved statistically significant reductions in Sjögren's d...
Read More — Novartis Ianalumab First Drug to Reduce Disease Activity and Patient Burden in Sjögren's Disease Phase III Trials »A Hidden Cancer Risk in APS-1: What a New Scoping Review Found About Head and Neck Malignancies
A scoping review of 19 APS-1 patients found that head and neck squamous cell carcinomas develop early, often without classic risk factors, a...
Read More — A Hidden Cancer Risk in APS-1: What a New Scoping Review Found About Head and Neck Malignancies »Antiphospholipid Syndrome Is Getting a Second Look: Emerging Therapies May Go Beyond Lifelong Blood Thinners
A new review in Arthritis & Rheumatology highlights how antiphospholipid syndrome is increasingly being understood as an antibody-mediated d...
Read More — Antiphospholipid Syndrome Is Getting a Second Look: Emerging Therapies May Go Beyond Lifelong Blood Thinners »Selective JAK1 Inhibitor Ivarmacitinib Shows Meaningful Benefit in Active Ankylosing Spondylitis Trial
A peer-reviewed study in Arthritis and Rheumatology found that ivarmacitinib, a selective JAK1 inhibitor, significantly improved symptoms in...
Read More — Selective JAK1 Inhibitor Ivarmacitinib Shows Meaningful Benefit in Active Ankylosing Spondylitis Trial »When Standard Treatments Are Not Enough: Rituximab Offers Hope for Refractory Ocular Cicatricial Pemphigoid
A case report in the journal Reports documents how rituximab, an anti-CD20 biologic, stabilized ocular cicatricial pemphigoid in a patient w...
Read More — When Standard Treatments Are Not Enough: Rituximab Offers Hope for Refractory Ocular Cicatricial Pemphigoid »Implantable Cell Therapy May Offer Path Toward Functional Cure for Addison's Disease
Research presented at ENDO 2025 describes bioprinted adrenal cortex tissue that, when implanted in animals, restored cortisol production fol...
Read More — Implantable Cell Therapy May Offer Path Toward Functional Cure for Addison's Disease »
News
Phase IIA Trial: Tulisokibart Brings Nearly Half of Crohn's Disease Patients Into Remission
A Phase II-A clinical trial led by Cedars-Sinai researchers found that tulisokibart, a monoclonal antibody targeting TL1A, brought nearly 50...
Read More — Phase IIA Trial: Tulisokibart Brings Nearly Half of Crohn's Disease Patients Into Remission »Meta-Analysis Evaluates the Efficacy and Safety of Rituximab for Primary Sjögren's Syndrome
A 2025 meta-analysis pooled data from multiple clinical trials to offer the most comprehensive picture yet of how well rituximab works for p...
Read More — Meta-Analysis Evaluates the Efficacy and Safety of Rituximab for Primary Sjögren's Syndrome »New Review Identifies Key Biomarkers for Diagnosing and Tracking ADEM and MOG Antibody Disease
A comprehensive 2025 review compiled the latest evidence on biomarkers that can improve diagnosis, predict relapses, and guide treatment for...
Read More — New Review Identifies Key Biomarkers for Diagnosing and Tracking ADEM and MOG Antibody Disease »Precision Antibody Therapy ART5803 Blocks NMDA Receptor Damage in Anti-NMDA Encephalitis Models
Researchers at Arialys Therapeutics published preclinical data in Nature Communications showing that ART5803, a humanized monovalent antibod...
Read More — Precision Antibody Therapy ART5803 Blocks NMDA Receptor Damage in Anti-NMDA Encephalitis Models »When ADEM Looks Like Migraine: A Case Study in Delayed Diagnosis
A 35-year-old man's ADEM was initially misdiagnosed as complex migraine, leading to dangerous delays in treatment. This case report from Heb...
Read More — When ADEM Looks Like Migraine: A Case Study in Delayed Diagnosis »